Tofacitinib as treatment for refractory dermatomyositis: A retrospective study from 2 academic medical centers

J Am Acad Dermatol. 2022 Feb;86(2):423-425. doi: 10.1016/j.jaad.2021.07.003. Epub 2021 Jul 8.

¹ Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: [email protected].
² Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
³ Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
⁴ Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
⁵ Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: [email protected].

No abstract available

Publication types